Data Insights
                                    By  Company Name
                                
                                No Filter Selected
                                    By  Disease Name
                                
                                No Filter Selected
                                    By  Drug Name
                                
                                No Filter Selected
                                    By Themes
                                
                                No Filter Selected
                                    Showing 2 results out of 2                                
                                
                                                Data Insights
                                                
                                        Cetuximab by Eli Lilly and Co for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Cetuximab is under clinical development by Eli Lilly and Co and currently in Phase II for Cutaneous Squamous Cell Carcinoma...
                                                Data Insights
                                                
                                        Cetuximab by Eli Lilly and Co for Anal Cancer: Likelihood of Approval
Cetuximab is under clinical development by Eli Lilly and Co and currently in Phase II for Anal Cancer. According to...
